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Cowden syndrome (CS; OMIM #158350) is a rare 
auto somal dominant disorder characterized by multiple 
hamartomas of ectodermal, mesodermal and endoder-
mal origins. CS patients have a high risk of developing 
breast, thyroid and endometrial cancers (1). Typical 
mucocutaneous symptoms include facial trichilemmomas 
(hamartomas of the infundibulum of the hair follicle), 
acral keratoses and mucocutaneous papules. Other 
muco­cutaneous­lesions­include­dermal­fibromas,­scrotal­
tongue and skin tags (2). Additional disease features may 
include adult-onset Lhermitte-Dulclos disease (LDD) (a 
dysplastic gangliocytoma of the cerebellum), macroce-
phaly, mental retardation and structural malformations 
in the genitourinary system (3). This list has recently 
been revised (4).
PTEN is a tumor suppressor gene located on chromo-
some­10q23.3.­It­encodes­a­phosphatase­that­influences­
the cell cycle, causing G1 arrest and apoptosis (5). 
PTEN hamartoma tumor syndromes (PHTS) are a group 
of disorders characterized by PTEN mutations and ha-
martomas of multiple organ systems. They include CS, 
Bannayan-Riley-Ruvalcaba syndrome (BRRS; OMIM 
#153480), Proteus syndrome, and Proteus-like syndrome 
(6). Some 85% of CS patients carry germline loss-of-
function mutations in the PTEN gene. Among PHTS, 
it has been reported that BRRS and CS share clinical 
characterisitics and represent a single entity. However, 
BRRS can be clinically differentiated from CS by hamar-
tous polyposis, macrocephaly, lipomatosis, hemangioma 
and a speckled penis.
CASE REPORT 
A 28-year-old woman presented with multiple flesh-colored 
papules on her face and multiple palmar keratoses (Fig. 1). 
Additionally, she had a history of papillary thyroid cancer, a 
cervical arteriovenous malformation (AVM) and a hemangioma 
on the right forearm. All of these conditions had been treated 
prior to her visiting our department. A subtotal thyroidectomy, 
total excision of the cutaneous hemangioma and incomplete 
embolization therapy for the cervical paraspinal AVM were 
conducted. A recent thyroid ultrasound had shown that four 
thyroid masses remained. A fine-needle aspiration biopsy revea-
led benign adenomatous hyperplasia. She had no abnormalities 
of the oral mucosa, such as oral mucosal papillomatosus. She 
was not mentally disabled and had normocephaly (height 164 
cm, 70th percentile; head circumference 55.4 cm, 55th percen-
tile). The patient denied any family history of mucocutaneous 
lesions, hemangiomas, thyroid disease or mental retardation. 
Routine physical examinations and breast self-examinations 
had revealed nothing abnormal. The results of laboratory tests, 
including a full blood cell count, biochemical analyses of the 
blood that assessed glucose levels and liver and renal function, 
and urinalysis, were either within normal limits or negative. 
Multiple biopsies from facial skin affected by papules revealed 
follicular plugging and hyperkeratosis (Fig. 2a). Histopatholo-
gical analysis of biopsy specimens from skin affected by palmar 
keratoses showed epidermal hyperplasia with hypergranulosis 
and marked orthokeratotic hyperkeratosis (Fig. 2b). 
Genomic DNA was prepared from peripheral blood leuko-
cytes for use in germline mutation analyses. We performed a 
polymerase chain reaction amplification of exons 1-9 of the 
PTEN gene and sequenced all of the exon and intron junctions 
bilaterally. We identified a novel germline heterozygous mu-
tation, c.209+4_7delAGTA, in exon 3 (Fig. 3). Furthermore, 
her 2-year-old daughter, who did not have any mucocutaneous 
lesions and displayed normocephaly (head circumference 
48.3 cm, 51.6%), was also found to be carrying this mutation. 
Through PCR amplification of PTEN mRNA, using following 
primers: PTEN F2, 5’-TCAAGAGGATGGATTCGACTT-3’; 
PTEN R2, 5’ –CGCCACTGAACATTGGAATA, we finally 
sequenced the patient’s mRNA.
DISCUSSION
According to the results of mRNA sequencing, the novel 
germline deletion mutation causes transcriptional skipping 
of­exon­3.­The­novel­germline­mutation­identified­in­this­
study is predicted to cause single amino acid substitution 
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Fig. 1. Multiple rice grain-sized papules were present on the face.
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(R55S) and deletion of amino acids 56-70 in PTEN’s N-
terminal­phosphatase­domain.­We­were­unable­to­confirm­
whether­or­not­the­modified­PTEN­molecule­was­synthe-
sized in vivo. 
PTEN contains two key domains: the N-terminal do-
main and the C-terminal domain. Most PTEN mutations 
occur within the N-terminal phosphatase domain (amino 
acids 1-185). Analysis of the structure of PTEN revealed 
that its phosphatase domain, although similar to those 
of other phosphatases, has a slightly larger active site. 
This larger active site is accessible to phospholipid 
substrates, a unique feature of PTEN (7). It is also a 
mutational hot spot. This is especially true of exon 5, 
which accounts for 20% of the entire coding sequence 
and encodes the catalytic core. Exon 5 carries about 40% 
of the germline mutations in this gene. Approximately 
two-thirds of all mutations are found in exons 5, 7 and 
8. Mutations in exon 3 have rarely been reported (8).
It has been demonstrated that genetic background and 
modifier­genes­more­strongly­influence­the­onset­and­
spectrum­of­ tumor­ formation­ than­ the­specific­PTEN 
mutation present (9).
Facial trichilemmomas, a hallmark of CS, were not 
detected, despite multiple skin biopsies of the facial 
papules being analyzed. Brownstein et al. (10) reported 
that biopsies of multiple facial skin lesions were neces-
sary in order to detect evidence of trichilemmomas. It 
has been reported that punctate palmoplantar keratoses 
in childhood without other mucocutaneous lesions may 
be a clue for the early diagnosis of PHTS (11). Our 
patient’s symptoms – multiple facial papules, palmar 
keratoses, papillary thyroid cancer, thyroid adenomatous 
hyperplasias and a germline PTEN mutation – strongly 
suggest that the PTEN hamartoma tumor syndrome she 
is suffering from is CS. 
Our patient exhibited two vascular anomalies. One 
was a cutaneous hemangioma, and the other a cervical 
paraspinal AVM. Recently, Tan et al. (12) described 26 
patients with vascular anomalies and PTEN mutations. 
They­identified­AVMs­in­54%­of­the­patients­with­PTEN 
mutations. This high frequency may be explained by 
the make-up of the study population, which included 
individuals who had been treated at a vascular anomalies 
center. None suffered from hemangiomas or other pure 
vascular tumors, and paraspinal AVM was found in only 
two cases.  
There is growing evidence that PTEN has an anti-
angiogenic effect (13) and it inhibits endothelial tube 
formation induced by vascular endothelial growth fac-
tor (VEGF) (14). Furthermore, loss of the PTEN gene 
results in subsequent VEGF expression (15).
Our patient wanted her daughter to undergo genetic 
testing, although she did not have any features of CS, 
including mucocutaneous lesions and macrocephaly. 
Examination of the daughter revealed her to be car-
rying the same germline PTEN mutation, and she was 
recommended for surveillance according to NCCN 
criteria (2).
The authors declare no conflict of interest.
REFERENCES
Lloyd KM 21. nd, Dennis M. Cowden’s disease: a possible new 
symptom complex with multiple system involvement. Ann 
Intern Med 1963; 58: 136–142.
Pilarski R. Cowden Syndrome: A Critical Review of the 2. 
Clinical Literature. J Genet Counsel 2009; 18: 13–27.
Eng C. Will the real Cowden syndrome please stand up: revi-3. 
sed diagnostic criteria. J Med Genet 2000; 37: 828–830.
National Comprehensive Cancer Network. Cowden Syn-4. 
drome Testing Criteria. Practice Guideline in Oncology, Vol. 
1. 2008. Available at: http://www.nccn.org/professionals/
physician_gls (retrieved December 10 2009).
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, 5. 
et al. PTEN, a putative protein tyrosine phosphatase gene 
mutated in human brain, breast, and prostate cancer. Science 
1997; 275: 1943–1947.
Eng C. PTEN: one gene, many syndromes. Hum Mutat 6. 
2003; 22: 183–198.
Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama 7. 
T, Shi Y, et al. Crystal structure of the PTEN tumor suppres-
sor: implications for its phosphoinositide phosphatase acti-
vity and membrane association. Cell 1999; 99: 323–334.
Waite KA, Eng C. Protean PTEN: form and function. Am 8. 
J Hum Genet 2002; 70: 829–844.
Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J, 9. 
et al. Genetic background controls tumor development in 
PTEN-deficient­mice.­Cancer­Res­2006;­66:­6492–6496.
Brownstein MH, Mehregan AH, Bikowski JD, Lupulescu 10. 
A, Patterson JC. The dermatopathology of Cowden’s syn-
drome. Br J Dermatol 1979; 100: 667–673.
Ferran M, Bussaglia E, Matias-Guiu X, Pujol RM. Bila-11. 
teral and symmetrical palmoplantar punctate keratoses in 
Fig. 2. Histopathological features. (a) Follicular keratotic plugging of a facial 
papule. (b) Acanthosis with hypergranulosis and marked orthokeratosis in a 
palmar­keratosis.­(a,­b)­H&E,­original­magnification­×100.
Fig. 3. A four-nucleotide deletion (c.209+4_7delAGTA) in exon 3 of the 
PTEN gene. Arrow, deleted nucleotides; W, wild-type allele; M, mutated 
allele.
Acta Derm Venereol 91
90 Letters to the Editor
childhood: a possible clinical clue for an early diagnosis of 
PTEN hamartoma-tumour syndrome. Clin Exp Dermatol 
2009; 34: e28–e30.
Tan WH, Baris HN, Burrows PE, Robson CD, Alomari AI, 12. 
Mulliken JB, et al. The spectrum of vascular anomalies in 
patients with PTEN mutations: implications for diagnosis 
and management. J Med Genet 2007; 44: 594–602.
Su JD, Mayo LD, Donner DB, Durden DL. PTEN and 13. 
phosphatidylinositol 3’-kinase inhibitors up-regulate p53 
and block tumor-induced angiogenesis: evidence for an 
effect on the tumor and endothelial compartment. Cancer 
Res 2003; 63: 3585–3592.
Leslie NR, Downes CP. PTEN: The down side of PI 3-kinase 14. 
signalling. Cell Signal 2002; 14: 285–295.
Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons 15. 
R,­Greenberg­N,­et­al.­Haploinsufficiency­of­the­PTEN­tu-
mor suppressor gene promotes prostate cancer progression. 
Proc Natl Acad Sci U S A 2001; 98: 11563–11568.
Acta Derm Venereol 91
